Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

66.64 +9.64 (+16.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
The company is working on a treatment for a rare, inherited disease that causes copper to build up in the body. 
Via Investor's Business Daily
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Recap: Monopar Therapeutics Q4 Earnings
 
Via Benzinga
3 Momentum Stocks Soaring Into 2025 and Beyond
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential. 
Via MarketBeat
Topics Stocks
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
What's Going On With Monopar Therapeutics Shares Friday?
Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. 
Via Benzinga
Topics Stocks
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. 
Via Benzinga
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too. 
Via InvestorPlace
Topics Regulatory Compliance
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023
MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
Crude Oil Down 2%; Maravai LifeSciences Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The Dow traded up 0.36% to 39,209.32 while the NASDAQ rose 0.01% to 16,042.80.... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.